Good things come in small packages: Therapeutic anti-tumor immunity induced by microrna nanoparticles

OncoImmunology

Volumn 1, Issue 6, 2012, Pages 968-970

  Cubillos Ruiz, Juan R ^a,b   Sempere, Lorenzo F ^c   Conejo Garcia, Jose R ^d  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c DARTMOUTH MEDICAL SCHOOL   (United States)

^d WISTAR INSTITUTE   (United States)

Author keywords

Dendritic cell; Immunosuppression; MicroRNA; Ovarian cancer; Tumor immunology

Indexed keywords

ANTINEOPLASTIC AGENT; MICRORNA; MICRORNA 155; NANOPARTICLE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER THERAPY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG TARGETING; GENE; GENE SILENCING; HUMAN; IMMUNE DEFICIENCY; METASTASIS; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; SATB1 GENE; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY;

EID: 84886945120     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.20020     Document Type: Article

References (9)

1. Zhang L, Volinia S, Bonome T, Calin GA, Greshock J, Yang N, et al. Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci USA 2008; 105:7004-9; PMID:18458333; http://dx.doi.org/10.1073/pnas.0801615105.
2. Cubillos-Ruiz JR, Rutkowski M, Conejo-Garcia JR. Blocking ovarian cancer progression by targeting tumor microenvironmental leukocytes. Cell Cycle 2010; 9:260-8; PMID:20023378; http://dx.doi.org/10.4161/ cc.9.2.10430.
3. Scarlett UK, Rutkowski MR, Rauwerdink AM, Fields J, Escovar-Fadul X, Baird J, et al. Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. J Exp Med 2012; 209:495-506; PMID:22351930; http://dx.doi.org/10.1084/ jem.20111413.
4. Cubillos-Ruiz JR, Engle X, Scarlett UK, Martinez D, Barber A, Elgueta R, et al. Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic anti-tumor immunity. J Clin Invest 2009; 119:2231-44; PMID:19620771.
5. Rodriguez A, Vigorito E, Clare S, Warren M V, Couttet P, Soond DR, et al. Requirement of bic/microRNA-155 for normal immune function. Science 2007; 316:608-11; PMID:17463290; http://dx.doi.org/10.1126/sci-ence.1139253.
6. Cubillos-Ruiz JR, Baird JR, Tesone AJ, Rutkowski MR, Scarlett UK, Camposeco-Jacobs AL, et al. Reprogramming tumor-associated dendritic cells in vivo using microRNA mimetics triggers protective immunity against ovarian cancer. Cancer Res 2012; (Epub ahead of press); PMID:22307839; http://dx.doi.org/10.1158/0008-5472.CAN-11-3160.
7. Cubillos-Ruiz JR, Fiering S, Conejo-Garcia JR. Nanomolecular targeting of dendritic cells for ovarian cancer therapy. Future Oncol 2009; 5:1189-92; PMID:19852731; http://dx.doi.org/10.2217/ fon.09.101.
8. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, et al. Intratumoral T cells, recurrence and survival in epithelial ovarian cancer. N Engl J Med 2003; 348:203-13; PMID:12529460; http://dx.doi.org/10.1056/NEJMoa020177.
9. Beatty GL, Chiorean EG, Fishman M P, Saboury B, Teitelbaum UR, Sun W, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011; 331:1612-6; PMID:21436454; http://dx.doi.org/10.1126/sci-ence.1198443.